https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53765 Wed 28 Feb 2024 15:59:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50606 Wed 28 Feb 2024 15:56:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50571 Wed 28 Feb 2024 15:53:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54297 Wed 28 Feb 2024 15:52:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50469 Wed 28 Feb 2024 15:49:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52688 Wed 28 Feb 2024 15:49:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54338 Wed 28 Feb 2024 15:14:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50453 Wed 28 Feb 2024 15:13:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38722 Wed 19 Jan 2022 09:36:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44505 Wed 16 Aug 2023 09:41:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38441 90%) recognised key recommendations for asthma management such as smoking cessation, appropriate vaccinations, and the continuation of prescribed asthma medications. Conclusion: Although midwives appear aware of key clinical recommendations for optimal antenatal asthma management, low referral to clinical practice guidelines and lack of knowledge and confidence was evident. Further research is required to determine what care pregnant women with asthma are actually receiving and identify strategies to improve antenatal asthma management by midwives.]]> Wed 15 Sep 2021 14:46:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11837 Wed 11 Apr 2018 16:30:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15375 Wed 11 Apr 2018 15:55:53 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15981 Wed 11 Apr 2018 14:59:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1059 Wed 11 Apr 2018 14:05:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15377 Wed 11 Apr 2018 13:30:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16765 Wed 11 Apr 2018 13:10:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21150 Wed 11 Apr 2018 12:44:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15695 Wed 11 Apr 2018 12:28:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27569 Wed 11 Apr 2018 11:56:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24115 Wed 11 Apr 2018 11:19:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13797 Wed 11 Apr 2018 11:18:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17958 Wed 11 Apr 2018 09:41:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14143 Wed 11 Apr 2018 09:25:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31352 Wed 10 Nov 2021 15:04:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32663 Wed 10 Nov 2021 15:04:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33415 Wed 10 Nov 2021 15:04:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14664 Wed 04 Sep 2019 11:10:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44806 Wed 01 May 2024 12:05:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46987 Tue 13 Dec 2022 09:28:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53621 Tue 12 Dec 2023 15:19:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36051 Thu 28 Oct 2021 13:04:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34994 Thu 28 Oct 2021 13:04:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26123 Thu 28 Oct 2021 13:04:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23093 Thu 28 Oct 2021 13:04:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26089 Thu 28 Oct 2021 13:03:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35593 Thu 28 Oct 2021 13:03:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31397 IL1R1, IL1R2, and IL1RN), and signaling molecules (IRAK2, IRAK3, and PELI1), were measured in sputum using real-time quantitative polymerase chain reaction. Mediators were compared between the frequent (≥2 exacerbations in the 12 months) and infrequent exacerbators, and the predictive relationships investigated using receiver operating characteristic curves and area under the curve (AUC) values. Results: Of the 95 participants, 89 completed the exacerbation follow-up, where 30 participants (n=22 COPD, n=8 asthma) had two or more exacerbations. At the baseline visit, expressions of IRAK2, IRAK3, PELI1, and IL1R1 were elevated in participants with frequent exacerbations of both asthma and COPD combined and separately. In the combined population, sputum gene expression of IRAK3 (AUC=75.4%; P<0.001) was the best predictor of future frequent exacerbations, followed by IL1R1 (AUC=72.8%; P<0.001), PELI1 (AUC=71.2%; P<0.001), and IRAK2 (AUC=68.6; P=0.004). High IL-1 pathway gene expression was associated with frequent prior year exacerbations and correlated with the number and severity of exacerbations. Conclusion: The upregulation of IL-1 pathway mediators is associated with frequent exacerbations of obstructive airway disease. Further studies should investigate these mediators as both potential diagnostic biomarkers predicting at-risk patients and novel treatment targets]]> Thu 28 Oct 2021 13:03:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23689 Thu 28 Oct 2021 13:03:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33793 –/–) mice had reduced mucin (MUC) 5 AC levels, but not MUC5B levels, in the airways as compared with wild‐type (WT) mice. Fbln1c interacted with fibronectin and periostin that was linked to collagen deposition around the small airways. Fbln1c^–/– mice with AAD also had reduced numbers of α‐smooth muscle actin‐positive cells around the airways and reduced airway contractility as compared with WT mice. After HDM challenge, these mice also had fewer airway inflammatory cells, reduced interleukin (IL)‐5, IL‐13, IL‐33, tumour necrosis factor (TNF) and CXCL1 levels in the lungs, and reduced IL‐5, IL‐33 and TNF levels in lung‐draining lymph nodes. Therapeutic targeting of Fbln1c reduced the numbers of GATA3‐positive Th2 cells in the lymph nodes and lungs after chronic HDM challenge. Treatment also reduced the secretion of IL‐5 and IL‐13 from co‐cultured dendritic cells and T cells restimulated with HDM extract. Human epithelial cells cultured with Fbln1c peptide produced more CXCL1 mRNA than medium‐treated controls. Our data show that Fbln1c may be a therapeutic target in chronic asthma.]]> Thu 28 Oct 2021 13:02:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24324 Tropheryma whipplei and Haemophilus influenzae in sputum. Adults with neutrophilic asthma had reduced bacterial diversity and species richness. Tropheryma was identified and confirmed with real-time PCR in 12 (40%) participants. Haemophilus occurred most often in a group of younger atopic males with an increased proportion of neutrophils. PCR confirmed the presence of H. influenzae in 35 (76%) participants with poorly controlled asthma. There are phenotype-specific alterations to the airway microbiome in asthma. Reduced bacterial diversity combined with a high prevalence of H. influenzae was observed in neutrophilic asthma, whereas eosinophilic asthma had abundant T. whipplei.]]> Thu 28 Oct 2021 13:02:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25846 Thu 28 Oct 2021 12:37:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45375 Thu 27 Oct 2022 16:54:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:416 Thu 25 Jul 2013 09:10:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:407 Thu 25 Jul 2013 09:09:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38505 Thu 18 Nov 2021 09:58:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48433 Thu 16 Mar 2023 14:17:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54288 Thu 15 Feb 2024 14:47:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35868 Thu 14 Apr 2022 11:01:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15252 Thu 11 Jul 2019 11:46:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8221 Thu 11 Jul 2019 11:43:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7732 Thu 06 Dec 2018 12:06:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25385 Herissantia tiubae (HtE) is a Brazilian plant used in folk medicine to treat inflammatory diseases. Our aim was to determine whether the HtE has antiinflammatory and anxiolytic effects in a murine model of asthma. Ovalbumin(OVA)-sensitized BALB/c mice were treated with HtE (50, 100, or 200mg/kg) or dexamethasone before each OVA challenge. After the last challenge, animals were subjected to anxiety tests and respiratory measurements. Following euthanasia, we quantified immune cells in the bronchoalveolar lavage (BAL), serum IgE titer and cytokine levels, cellular infiltration and mucus content in the lung tissues, and cellular composition of the mediastinal lymph nodes. OVA challenge in sensitized animals caused: (1) reduction of mean respiratory and dominant respiratory rate (from 398±12 to 286±20 cicles per minute (cpm) and from 320±14 to 162±15 cpm, respectively); (2) increase in behavioral markers of anxiety tests; (3) substantial pro-inflammatory effects, including rise in OVA-specific IgE titer (from 0 to 1:2048) and these inflammatory effect diminished the titer to 1:512 after HtE treatment; rise in plasma IL-13 (from 13 ng/mL in saline to 227 ng/mL in OVA and HtE treatment restored to 1.29 ng/mL; rise in total BAL cell count (from 0.742 cells/ mL in saline to 11.77 cells/mL in OVA), with prominent eosinophilia. H. tiubae extract affected respiratory parameters similarly to aminophylline, behavioral changes comparable to diazepam, and inflammation being as efficient as dexamethasone. H. tiubae extract (HtE) possesses both anti-inflammatory and anxiolytic properties in the murine model of asthma.]]> Thu 04 Nov 2021 10:38:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30164 Thu 04 Nov 2021 10:38:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4601 Sat 24 Mar 2018 10:13:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8465 Sat 24 Mar 2018 08:42:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7560 Sat 24 Mar 2018 08:42:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8406 Sat 24 Mar 2018 08:40:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7452 Sat 24 Mar 2018 08:38:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8664 Sat 24 Mar 2018 08:38:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7009 Sat 24 Mar 2018 08:38:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7690 Sat 24 Mar 2018 08:33:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1310 0.05). Corticotropin-releasing hormone (CRH), a potent vasodilator that acts via the nitric oxide pathway, caused a dose-dependent vasodilatory response in all placentae in vitro. However, CRH-induced dilation was significantly reduced in moderate and severe asthmatics (ANOVA, p < 0.05). Vasoconstrictor responses to potassium chloride and prostaglandin F2alpha were reduced in placentae from moderate and severe asthmatic women (ANOVA, p < 0.05). These studies demonstrate significant differences in placental vascular function in pregnancies complicated by asthma, which may relate directly to the asthma or be a consequence of the associated glucocorticoid treatment. These changes in vascular function in asthmatic pregnancies may contribute to the low-birthweight outcome observed in this condition.]]> Sat 24 Mar 2018 08:32:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1274 2.5%) was 45% in the wheeze group, which was significantly higher than the control group (9.35%, p = 0.04). Eosinophilic bronchitis was present in two children with cough (20%) and two with chest colds (15%, p > 0.05 versus control). In these groups, eosinophilic bronchitis was not associated with airway hyperresponsiveness (AHR) to hypertonic saline (p > 0.05). Children with cough and chest colds reported greater exposure to environmental tobacco smoke. In conclusion, this community-based survey of children with chronic respiratory symptoms has shown that wheeze is a good discriminator for the presence of eosinophilic bronchitis, and that persistent cough and recurrent chest colds without wheeze should not be considered a variant of asthma. Eosinophilic bronchitis did occur in a significant minority of these "variant asthma" syndromes.]]> Sat 24 Mar 2018 08:32:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1373 Sat 24 Mar 2018 08:28:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1763 Sat 24 Mar 2018 08:27:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14790 Sat 24 Mar 2018 08:26:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14649 Sat 24 Mar 2018 08:20:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13283 Sat 24 Mar 2018 08:15:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10730 Sat 24 Mar 2018 08:09:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11339 Sat 24 Mar 2018 08:08:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16925 Sat 24 Mar 2018 08:00:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18462 3% and > 61% respectively. Peripheral blood monocytes were isolated (n = 61) and sputum macrophages were isolated from a subgroup of patients with asthma (n = 14), using immunomagnetic cell separation. RNA and nuclear proteins were extracted and quantified. Enzyme activity was assessed using fluorescent assays and gene expression of EP300, KAT2B, CREBBP, and HDACs 1, 2 and 3 were measured by qPCR. Results: There was a significant inverse association between blood monocyte HAT and HDAC activity (r = −0.58, P < 0.001). NA was associated with increased blood monocyte HAT enzyme activity (P = 0.02), decreased HDAC activity (P = 0.03), and increased HAT: HDAC ratio (P < 0.01) compared with eosinophilic asthma. There were no differences in gene expression of EP300, KAT2B, CREBBP, or HDACs 1, 2 and 3 in blood monocytes from subjects with asthma or inflammatory phenotypes of asthma. There was no effect of inhaled corticosteroid use, poor asthma control, or asthma severity on HAT/HDAC activities. Sputum macrophages had increased expression of KAT2B in eosinophilic compared with paucigranulocytic asthma. Conclusions and Clinical Relevance: Neutrophilic airway inflammation is associated with increased HAT and reduced HDAC activity in blood monocytes, demonstrating further systemic manifestations relating to the altered inflammatory gene transcription profile of neutrophilic asthma.]]> Sat 24 Mar 2018 07:59:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20580 Sat 24 Mar 2018 07:55:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20982 Sat 24 Mar 2018 07:54:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18331 Sat 24 Mar 2018 07:52:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21345 n = 10), and patients with NEA (n = 22) or eosinophilic asthma (EA) (n = 15) using flow cytometry. Results: Granzyme B expression and the ratio of granzyme B to PI-9 positive cells were highest in those with NEA for both CD3+ and CD4+ T cells. The expression of granzyme B was not statistically different between patients with NEA and EA; however, the ratio of granzyme B to PI-9 positive cells for CD3+ T cells was significantly higher in those with NEA compared with EA. Conclusions: Induced sputum provides a non-invasive tool for investigating T cell cytotoxic mediators in the various asthma subtypes. Granzyme B expression is increased in NEA and the contribution of granzyme B to chronic inflammation requires further study.]]> Sat 24 Mar 2018 07:51:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29169 p = 0.480) and uncontrolled asthma at =2 study visits (21.3-11.3%; p = 0.078). Conclusions: These findings demonstrate the potential impact of an AMS in improving asthma control during pregnancy, supporting the need for an adequately powered RCT to determine its clinical- and cost-effectiveness.]]> Sat 24 Mar 2018 07:35:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4310 Sat 24 Mar 2018 07:22:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4768 Sat 24 Mar 2018 07:20:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4797 Sat 24 Mar 2018 07:20:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22281 Sat 24 Mar 2018 07:17:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54592 Sat 02 Mar 2024 11:19:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38585 in vitro airway epithelial infection models using high multiplicity of infection (MOI) and lacking genome-wide, time course analyses have obscured the role of epithelial innate anti-viral immunity in asthma and COPD. To address this, we developed a low MOI rhinovirus model of differentiated primary epithelial cells obtained from healthy, asthma and COPD donors. Using genome-wide gene expression following infection, we demonstrated that gene expression patterns are similar across patient groups, but that the kinetics of induction are delayed in cells obtained from asthma and COPD donors. Rhinovirus-induced innate immune responses were defined by interferons (type-I, II, and III), interferon response factors (IRF₁, IRF₃, and IRF₇), TLR signaling and NF-κB and STAT₁ activation. Induced gene expression was evident at 24 h and peaked at 48 h post-infection in cells from healthy subjects. In contrast, in cells from donors with asthma or COPD induction was maximal at or beyond 72–96 h post-infection. Thus, we propose that propensity for viral exacerbations of asthma and COPD relate to delayed (rather than deficient) expression of epithelial cell innate anti-viral immune genes which in turns leads to a delayed and ultimately more inflammatory host immune response.]]> Mon 29 Jan 2024 18:03:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38401 Mon 29 Jan 2024 17:48:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46274 Mon 14 Nov 2022 15:28:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46219 Mon 14 Nov 2022 12:04:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46221 Mon 14 Nov 2022 12:04:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43034 Mon 12 Sep 2022 11:49:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38495 Mon 09 May 2022 16:16:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40279 Mon 08 Aug 2022 11:55:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43398 Mon 04 Sep 2023 13:18:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36441 Mon 04 May 2020 13:05:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21995 Fri 25 May 2018 17:44:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34249 Fri 22 Feb 2019 16:55:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23240 Fri 22 Apr 2022 10:21:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46107 −2) versus healthy-weight (BMI <25 kg·m⁻²) subjects with asthma. Design Databases including CINAHL (Cumulative Index to Nursing and Allied Health Literature), Cochrane, Embase and MEDLINE were searched up to July 2019 for English-language studies that recorded medication use or dose in obese and healthy-weight adults with asthma. A critical appraisal checklist was utilised for scrutinising methodological quality of eligible studies. Meta-analysis was performed and heterogeneity was examined with the use of the Chi-squared test. This review was conducted based on a published protocol (www.crd.york.ac.uk/PROSPERO CRD42020148671). Results Meta-analysis showed that obese subjects are more likely to use asthma medications, including short-acting β2-agonists (OR 1.75, 95% CI 1.17–2.60; p=0.006, I²=41%) and maintenance oral corticosteroids (OR 1.86, 95% CI 1.49–2.31; p<0.001, I2=0%) compared to healthy-weight subjects. Inhaled corticosteroid (ICS) dose (µg·day⁻¹) was significantly higher in obese subjects (mean difference 208.14, 95% CI 107.01–309.27; p<0.001, I²=74%). Forced expiratory volume in 1 s (FEV₁) % predicted was significantly lower in obese subjects (mean difference −5.32%, 95% CI −6.75–−3.89; p<0.001, I²=42%); however, no significant differences were observed in FEV₁/forced vital capacity (FVC) ratio between groups. Conclusions We found that obese subjects with asthma have higher use of all included asthma medication classes and higher ICS doses than healthy-weight asthma subjects, despite lower FEV₁ and a similar FEV₁/FVC %. A better understanding of the factors driving increased medication use is required to improve outcomes in this subgroup of asthmatics.]]> Fri 11 Nov 2022 15:35:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22673 Fri 11 Jun 2021 13:31:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54653 Fri 08 Mar 2024 09:54:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33714 Fri 07 Dec 2018 16:47:51 AEDT ]]>